A Phase 3 interventional study of Glepaglutide in Short Bowel Syndrome, sponsored by Zealand Pharma. Completed at 19 sites in 8 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Short Bowel Syndrome with a site in Germany — 4 open to participants now, 6 under way, 4 of them phase 3. Short Bowel Syndrome · Germany.
Among the 17 studies in Short Bowel Syndrome with a site in Germany, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 12 in phase 3, and was the 12th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →4 of the 17 studies in Short Bowel Syndrome with a site in Germany are open now. Recruiting first, the newest first:
VectivBio AG · Sites in Germany, United States, Argentina and 19 more countries
Ages 18+
Zealand Pharma · Sites in Germany, United States, Austria and 11 more countries
Ages 18–90
Napo Therapeutics, S.p.A. · Sites in Germany, Italy
Ages 18+
Hanmi Pharmaceutical Company Limited · Sites in Germany, United States, Belgium and 5 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2021.
This study's enrollment of 84 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 86 across the 15 interventional studies, 193 across the 2 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 8 most frequent:
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Zealand Pharma has 7 studies filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Short Bowel Syndrome with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05018286Phase 3VectivBio AGOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | 2027-10-30 |
| NCT06904872Napo Therapeutics, S.p.A.Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Short Bowel Syndrome with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
Drug: Glepaglutide
Glepaglutide will be delivered in a single-use autoinjector.
Also known as: ZP1848
Incidence and type of Adverse Events (AEs)
For AEs with onset or worsening following Visit 1
Time frame: After 108 weeks
Incidence and type of Serious Adverse Events (SAEs)
For AEs with onset or worsening following Visit 1
Time frame: After 108 weeks
Incidence and type of Adverse Events of Special Interest (AESIs)
For AEs with onset or worsening following Visit 1
Time frame: After 108 weeks
Change in body temperature
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in heart rate
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in blood pressure
Seated diastolic and systolic blood pressure
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in body weight
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Number of participants with clinically significant changes in 12-Lead electrocardiogram (ECG)
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in hematology - hemoglobin
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in hematology - hematocrit
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in hematology - white blood cell count
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in hematology - platelet count
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - sodium
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - potassium
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - chloride
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - bicarbonate
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - blood urea nitrogen
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - creatinine
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - creatinine clearance
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - glucose
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - calcium
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - phosphorous
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - alkaline phosphatase
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - alanine aminotransferase (ALT)
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - aspartate aminotransferase (AST)
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - International Normalized Ratio (INR)
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - gamma-glutamyl transferase (GGT)
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - lactic dehydrogenase
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - conjugated bilirubin
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - total bilirubin
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - total protein
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - albumin
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - amylase
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - uric acid
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in biochemistry - C-reactive protein
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in urinalysis - blood
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in urinalysis - glucose
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in urinalysis - leukocytes
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in urinalysis - pH
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in urinalysis - osmolality
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in urinalysis - protein
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in urinalysis - sodium
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Change in urinalysis - potassium
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Anti-glepaglutide antibodies
Time frame: Week 0, Week 108
Antibody reactivity to ZP1848
Time frame: Week 0, Week 108
Cross-reactivity to glucagon-like peptide-2 (GLP-2)
Time frame: Week 0, Week 108
Glepaglutide neutralizing antibodies
Time frame: Week 0, Week 108
Reduction in weekly Parenteral Support (PS) volume
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Reduction of at least 20 percent in weekly PS volume
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Reduction in days on PS greater than or equal to 1 day per week
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Reduction in weekly PS volume of 100 percent (weaned off)
Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Apr 2026, 58 months.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 58 months is above that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glepaglutide